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Abstract
Passive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious
diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the
elderly, the chronically immunosuppressed, pregnant women, infants and those with chronic diseases. The aim of this study
was to optimise current methods used to generate ovine polyclonal antibodies. Polyclonal antibodies to baculovirus-
expressed recombinant influenza haemagglutinin from A/Puerto Rico/8/1934 H1N1 (PR8) were elicited in sheep using
various immunisation regimens designed to investigate the priming immunisation route, adjuvant formulation, sheep age,
and antigen dose, and to empirically ascertain which combination maximised antibody output. The novel adjuvant
CoVaccine HT
TM was compared to Freund’s adjuvant which is currently the adjuvant of choice for commercial production of
ovine polyclonal Fab therapies. CoVaccine HT
TM induced significantly higher titres of functional ovine anti-haemagglutinin
IgG than Freund’s adjuvant but with fewer side effects, including reduced site reactions. Polyclonal hyperimmune sheep
sera effectively neutralised influenza virus in vitro and, when given before or after influenza virus challenge, prevented the
death of infected mice. Neither the age of the sheep nor the route of antigen administration appeared to influence antibody
titre. Moreover, reducing the administrated dose of haemagglutinin antigen minimally affected antibody titre. Together,
these results suggest a cost effective way of producing high and sustained yields of functional ovine polyclonal antibodies
specifically for the prevention and treatment of globally significant diseases.
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Introduction
Antigen-specific polyclonal antibodies are generated for a wide
array of purposes which range from fundamental laboratory
studies and protocols to passive immunotherapy for life threaten-
ing conditions including snake envenomation [1] and drug toxicity
[2]. Sheep are particularly attractive for the generation of passive
polyclonal immunotherapeutics as ovine antibody fragments have
demonstrated reduced immunogenicity and more consistent
biological function than those derived from other animals [3].
Furthermore, large quantities of serum can be repeatedly obtained
from sheep, with reduced maintenance costs and lower immune
boosting demands than other large animals such as horses [4].
Specifically, polyclonal ovine antibodies in the form of antigen-
binding antibody fragments or ‘Fab’ underlie the use of antibodies
in critical care situations such as snake envenomation and digoxin
toxicity [5]. Potential hypersensitivity reactions often associated
with administration of whole antibody are considerably reduced
by using these Fab fragments or their divalent counterpart F(ab)2.
Hence, this type of treatment has the potential to be readily
transferable to infectious disease management, particularly in light
of the increased incidence of drug resistance to circulating
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e68895pathogens [6,7] and the medley of undesirable side effects often
associated with conventional drug treatments [8,9,10]. Of
particular interest here is the applicability of this approach to
infections with viral pathogens such as influenza, as natural
immunity to many such viruses is facilitated through the action of
neutralising antibodies [3,11,12].
Whilst traditional vaccination reduces influenza-associated
mortality [13], it is least efficacious in the immunocompromised
individuals who are most susceptible to complications and
increased mortality [14,15], and who include pregnant women
[16]. Consequently, immunocompromised individuals make up
the majority of the many thousands of annual influenza-related
deaths [14,17], which provides the rationale for passive immuno-
therapy as influenza prophylaxis or treatment in these individuals
because additional time is not needed to generate an efficient
vaccine-induced adaptive immune response [18]. Indeed, passively
administered influenza-specific antibody has been shown to inhibit
influenza-induced mortality in rodents [19], although the selection
of a suitable clinically applicable passive immunotherapeutic will
be determined by its inherent neutralisation capacity, its safety as
well as its commercial scalability and overall cost effectiveness
[20]. These factors highlight the requirement for optimal efficiency
at every stage of the production process.
Whilst downstream processing methods for existing commercial
ovine polyclonal antibody preparations have been methodically
optimised [21,22,23], there has been limited investigation into the
best way to generate maximal antibody titres and overall yield of
effective antibody from the sheep themselves. Indeed, there are
few reports in the published literature directly comparing the
parameters that can influence humoral immune responses in sheep
[24]. This is particularly important considering that route of
administration, antigen dose and adjuvant are well recognised as
critical parameters in antibody production from other species
[25,26].
The route of immunisation can influence the induction of the
humoral immune responses [27] by dictating which population of
dendritic cells (DCs) interacts with antigen [28,29]. For instance,
subcutaneous immunisation is routinely applied commercially to
produce hyperimmune ovine sera [22,23] and facilitates antigen
interaction with skin-associated DCs, including Langerhans cells,
conventional DCs and macrophage-derived DCs [30]. Alterna-
tively, intraperitoneal immunisation promotes antigen interaction
with conventional DCs macrophages and plasmacytoid DCs,
which may be beneficial depending on the antigen type [31,32].
The functionality of site-specific DC subsets in sheep has not been
well studied and thus empirical assessment is required to
determine an optimal immunisation route. Antigen dose can also
influence the outcome of immunisation; too little antigen may
elicit inefficient responses [33], and too much antigen can promote
adverse effects and immunotolerance [24]. The standard antigen
dose used in generating ovine antisera varies widely (from
micrograms to as much as five grams per animal [24]) and this
uncertainty necessitates investigation of appropriate antigen
dosage for optimal antibody output. The choice of adjuvant is
another key factor in dictating both the quality and quantity of the
humoral immune response [25,34]. Adjuvants prolong and
augment the effects of vaccination through various mechanisms
which include increasing antigen persistence, stimulation of local
inflammation, upregulation of cytokines and immunomodulatory
factors, activation of phagocytic cells and promotion of antigen
presentation [35,36]. The current gold-standard for generation of
a humoral immune responses in animals is Freund’s adjuvant (FA),
a water-in-oil emulsion which is available in ‘complete’ or
‘incomplete’ formulations, that is, with or without heat-killed
Mycobacterium tuberculosis respectively [37]. This adjuvant primarily
works by increasing antigen persistence in the tissues [38] and
stimulating a foreign-body reaction which results in local
inflammation and recruitment of innate and adaptive immune
cells [39]. It is however often associated with the formation of
painful granulomas and can also result in tuberculin-type
hypersensitivity [40]. It is not approved for human use and
concerns with animal welfare have prompted investigation into
alternative adjuvants for use in animals [39].
The current study applies empirical methods to optimise anti-
A/Puerto Rico/8/1934 H1N1 (PR8) haemagglutinin (HA) ovine
polyclonal antibody production using FA and a proprietary
experimental adjuvant, CoVaccine HT
TM (CV) [36,41,42,43].
CoVaccine HT
TM is in clinical development and consists of
sucrose fatty acid sulphate esters (SFASE) immobilised on the oil
droplets of a submicron emulsion of squalane-in-water [41]. We
show that the age of sheep, the prime immunisation route, and
dose has minimal impact on the antibody titre, although CV
adjuvant induced superior anti-HA antibody titres than immuni-
sation regimens incorporating FA. The influenza-neutralisation
capacity of the anti-HA antibody was subsequently assessed by
haemagglutination-inhibition (HAI) assays and was found to
correlate closely with the antibody titres measured for each of
the variables. Finally, it was demonstrated that high titre ovine
hyperimmune serum can be successfully applied in a lethal in vivo
murine influenza challenge model to prevent mortality in both a
prophylactic and therapeutic context.
Materials and Methods
Recombinant Haemagglutinin Production
The HA sequence of A/Puerto Rico/8/1934 H1N1 (PR8)
H1N1 (NCBI accession: AF389118) from PR8-transfected AB1
malignant melanoma cells (AB1-HA) was PCR cloned into
pGEM-T Easy Vector system (Promega) using primers with
appropriate restriction sites and a C-terminal 6x-His tag.
Confirmed HA sequence was subsequently used to produce
recombinant baculovirus using the Bac-to-Bac expression system
(Invitrogen). Insect cells (Sf21) were maintained in sf900 SFM III
(Invitrogen) supplemented with L-glutamine (100 mg/ml), penicil-
lin (100 U/ml), gentamycin (100 mg/ml) and HEPES (10 mM,
pH 7.2) in roller bottle flasks at 27uC. Protein was produced by
infection of Sf21 insect cells 96 hours prior to protein harvest, and
cultures were supplemented with 100 mg/ml L-glutamine 24 hours
prior to harvest. Expressed protein was purified from cell lysate
using Ni-NTA Agarose beads (Qiagen) according to the manu-
facturer’s instructions before dialysis with PBS. Protein purity was
analysed by SDS-PAGE and anti-HA Western Blot and concen-
tration determined with BCA assay.
Immunisation and Sampling
Purified recombinant HA (rHA) antigen was diluted in PBS and
emulsified with an equal volume of complete FA for prime
immunisation or incomplete FA for boost immunisation (Gibco).
Groups of five 9-month old or 3-year old Border Leicester x
Merino ewes were immunised with 200 or 20 mg rHA in 4 ml
emulsion, either subcutaneously (SC) at 4 axillary sites or as a
bolus intraperitoneal (IP) injection (prime only). Alternatively,
antigen in PBS was gently mixed with an equal quantity of CV
suspension (Protherics Medicines Ltd) and sheep were immunised
with 2 ml emulsion SC at 4 axillary sites. Sheep were administered
a prime immunisation and a boost dose every 14 days for a total of
five boosts. Serum was sampled prior to each immunisation and
stored at 220uC.
Influenza Neutralising Antibodies from Sheep
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Briefly, EIA/RIA high-binding ELISA plates (Costar) were
coated with 10 mg/ml rHA overnight at 4uC. Plates were blocked
with 2% (w/v) BSA (1 hour, 37uC) and pre-immune or
hyperimmune sheep serum diluted as indicated in Figure S1 was
added to duplicate wells and incubated for 2 hours (37uC). Bound
ovine antibodies were detected with HRP-linked anti-ovine IgG
antibody (Sigma; 1 hour, 37uC). The plates were developed with
OPD substrate (Sigma), the reaction stopped with 3 M HCl and
the absorbance read at 490 nm. Absorbance readings from
negative control wells were subtracted from all readings. ELISA
analysis of serially diluted samples indicated that a dilution of 1/
50,000 could enable accurate comparison of a range of samples in
the linear portion of the curve. A representative figure has been
included in Figure S1.
Haemagglutination-inhibition (HAI) Assay
Diluted pre-immune or hyperimmune serum samples (1/400)
were pre-treated with chicken red blood cells (cRBC) to remove
non-specific agglutinins (2 hours, room temperature) and the HAI
assay was performed using a previously described method [44].
Briefly, treated serum (10 ml) was serially diluted 1/4 in duplicate
wells of a round-bottom 96-well plate before the addition of PR8
influenza virus (5 haemagglutination units in 30 ml). After 30
minutes incubation at room temperature, 0.5% (v/v) cRBC in
PBS (30 ml) was added to each well and gently mixed. Plates were
visualised over a light box after 45 minutes. The endpoint HAI
titre was recorded as the highest dilution of serum that was able to
completely inhibit the agglutination of cRBC by virus in duplicate
wells. Potential non-specific inhibition was discounted by the use of
receptor-destroying enzyme (Table S1).
Murine Model of Influenza Infection
Female 6–8 week old BALB/c mice were housed in PC2
defined pathogen-free conditions following institutional guidelines.
Groups of 5 mice were administered high titre anti-HA ovine
serum (1 ml) or PBS intraperitoneally, and challenged intranasally
24 hours later with 500 TCID50 PR8 influenza virus (32 ml). In the
treatment models, mice were challenged with virus twenty-four
hours prior to intraperitoneal administration of whole or diluted
serum or control PBS as a 1 ml injection. Weight and clinical score
of the mice were monitored and mice were euthanased upon
achieving 20% (w/w) weight loss.
Statistical Analysis
All statistical analysis was performed with GraphPad Prism
V4.00 software.
Ethics Statement
All animal experiments were approved by the SA Pathology/
CHN and, where appropriate, Primary Industries and Resources
South Australia animal ethics committees. All experiments were
conducted in accordance with National and Institutional ethical
guidelines.
Results
Intraperitoneal or Subcutaneous Prime Immunisation
Induces Similar Peak Anti-Haemagglutinin Antibody
Titres
Generally, antigen emulsified with FA is administered subcu-
taneously over multiple sites. However, it has been previously
demonstrated that intraperitoneal prime immunisation can yield
significantly higher antibody titres [45,46]. Therefore, to directly
compare these routes of prime immunisation, groups of sheep
were immunised either subcutaneously (four sites) or intraperito-
neally (bolus injection) with rHA emulsified in complete FA. Both
groups were boosted subcutaneously every two weeks with rHA in
incomplete FA for a total of five boosts.
Serum samples were collected fortnightly and the titre of anti-
HA immunoglobulin G (IgG) was analysed by ELISA. Assessment
of results by two-way repeated-measures ANOVA indicated no
significant difference between antibody titres during the induction
phase (weeks 2–12) of the immune response (Figure 1A). However
when ELISA data from all time points including twelve weeks
post-immunisation were analysed, a significant trend for higher
antibody titres was observed in the subcutaneously primed group
(Figure 1A; P,0.05), which may indicate a slower decline in
antibody titre for this group. Importantly, neither group exhibited
a significant difference in the ability of various serum dilutions to
inhibit haemagglutination of PR8 in an HAI assay (Figure 1B).
Based on these results, the subcutaneous prime immunisation was
selected for all subsequent comparisons.
CoVaccine HT
TM Elicits Significantly Higher Ovine Anti-
haemagglutinin Antibody Titres than Freund’s Adjuvant
The experimental adjuvant CoVaccine HT
TM is an oil-in-water
emulsion, which is designed with synthetic carbohydrate structures
on squalane microdroplets and which produces proinflammatory
responses through interaction with innate immune receptors,
including TLR-4 [41,47]. This adjuvant offers the advantage of
presenting amphipathic membrane target antigens in native
formation due to the squalane-in-water formulation. It has shown
efficacy in combination with a range of antigens including malarial
antigens [48], influenza glycoproteins [47] and gonadatropin-
releasing hormone [49]. In order to determine if CV is capable of
inducing anti-HA antibody responses comparable to those
generated with FA, sheep were primed with rHA either
traditionally emulsified with complete FA or gently mixed with
CV and boosted fortnightly with rHA in incomplete FA or CV
respectively. Serum samples were collected fortnightly and
analysed via ELISA and HAI assay.
Two-way repeated-measures ANOVA and post-test analysis
indicated that CV elicited significantly higher antibody titres
overall (P,0.01) and at multiple time-points post prime (P,0.05)
compared to FA (Figure 2A). Consistent with the ELISA results,
the CV group sera demonstrated significantly higher HAI capacity
than those from the FA group (P,0.05; Figure 2B), suggesting that
CV may be a good alternative to FA in future immunisation
regimens.
Age of Sheep did not Significantly Alter the Ability to
Generate High Anti- haemagglutinin Antibody Titres
It was hypothesised that younger sheep may produce higher
antibody titres than older sheep due to a potential age-related
decline in immunity in aged sheep. To assess the effect of sheep
age on antibody output, sheep at nine months or three years of age
were immunised subcutaneously with rHA either in complete/
incomplete FA or CV as described above. Serum samples taken
every two weeks were assessed by ELISA and HAI assays
(Figure 3). Analysis of ELISA results by two-way repeated-
measures ANOVA with Bonferroni post-tests revealed no signif-
icant difference between antibody titres overall, or at individual
time points for serum produced in young or old sheep by
administration of rHA emulsified in FA (Figure 3Ai) or CV
(Figure 3Bi). Similarly, there was no significant difference in the
Influenza Neutralising Antibodies from Sheep
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HAI assays in either the FA-immunised (Figure 3Aii) or CV-
immunised groups (Figure 3Bii). Consistent with previous results,
HAI titres for either old or young sheep immunised with rHA-FA
emulsion were significantly lower (P=0.001) than the correspond-
ing CV group (Figure 3Aii and Figure 3Bii respectively). These
results suggest that age does not impact on the quality of the
antigen-induced antibody response.
A Ten-fold Lower Dosage of Antigen did not Yield
Significantly Lower Anti-haemagglutinin Antibody Titres
Cost of antigen is an important factor in any immunisation
regimen, therefore to determine whether economic gains may be
made by immunisation with a lower dose of antigen, sheep were
immunised subcutaneously with 200 mgo r2 0mg rHA either in FA
or CV as previously described. Serum samples taken every two
weeks were subsequently analysed by ELISA and HAI assays
(Figure 4). Statistical scrutiny revealed no significant difference in
antibody titre between high-dose and low-dose FA groups as
indicated by ELISA (Figure 4Ai) and HAI results (Figure 4Aii). In
comparison, significant differences were observed within the CV
groups in both the ELISA assay (Figure 4Bi; P,0.05) and HAI
assay (Figure 4Bii; P,0.05), however the magnitude of the
decrease in the low-dose group was comparatively small. Indeed,
Figure 1. Different routes of prime immunisation yield similar
anti-HA antibody titres. Sheep (n=5) were immunised with 200 mg
rHA SC or IP in complete FA. Sheep were boosted SC every two weeks
to a total of five boosts in incomplete FA (indicated by arrows). Pre-
immune (time 0) or hyperimmune serum samples were analysed for
anti-HA IgG via ELISA (1/50, 000 dilution) (A), and HAI(B). Data are
expressed as the mean 6 SEM. Two-way repeated-measures ANOVA
was applied to evaluate significance which is denoted as thus:
*=P,0.05, **=P,0.01, ***=P,0.001, ns=not significant.
doi:10.1371/journal.pone.0068895.g001
Figure 2. CoVaccine HT
TM adjuvant elicits significantly higher
anti-HA antibody titres than Freund’s adjuvant. Sheep (n=5)
were immunised SC with rHA (200 mg) in complete FA or CoVaccine
HT
TM (CV). Sheep were boosted similarly every two weeks (five boosts
indicated by arrows) with rHA in incomplete FA or CV. Pre-immune
(time 0) or hyperimmune serum samples were analysed for anti-rHA IgG
via ELISA (1/50, 000 dilution) (A) and HAI (B). Data are represented as
the mean 6 SEM. Two-way repeated-measures ANOVA with Bonferroni
post-test was applied to evaluate significance which is denoted as thus:
*=P,0.05, **=P,0.01, ***=P,0.001, ns=not significant.
doi:10.1371/journal.pone.0068895.g002
Figure 3. Nine-month old and three-year old sheep produce
similar anti-HA antibody titres. Sheep (n=5) at either nine months
(young) or three years (old) were immunised SC with 200 mg of rHA in
complete FA (A) or CV (B). Sheep were subsequently boosted SC every
two weeks to a total of five boosts in incomplete FA or CV (indicated by
arrows). Pre-immune (time 0) or hyperimmune serum samples were
analysed for anti-rHA IgG via ELISA (1/50, 000 dilution) (Ai, Bi) and HAI
(Aii, Bii). Data are expressed as the mean 6 SEM. Two-way repeated-
measures ANOVA with Bonferroni post-test was applied to evaluate
significance; ns=not significant.
doi:10.1371/journal.pone.0068895.g003
Influenza Neutralising Antibodies from Sheep
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isons revealed a significant difference in HAI titre at only one time
point. Importantly, HAI results of CV group sera again revealed a
more than ten-fold increase in mean endpoint serum dilution for
both the high and low dose rHA over that observed with FA-
induced sera (Figure 4Bii vs Figure 4Aii). These data supports the
use of a lower antigen dose to elicit comparably high quantities of
anti-HA antibody whilst reducing costs associated with antigen
production.
CoVaccine HT
TM Induced Fewer Adverse Site Reactions as
Compared to Freund’s Adjuvant
As FA immunisation often induces site-specific reactions, it was
necessary to determine whether CV similarly induced local
inflammatory reactions at the immunisation site. Observational
data were collected twelve weeks post-prime where the number
and size of palpable subcutaneous lumps at each site was recorded,
and sites were given a rating on a graded system (denoted in
Figure 5). No significant differences in size or number of reactive
sites were observed within adjuvant groups in the age and antigen
dose experiments (data not shown); therefore observational data
from all sheep receiving each subcutaneous immunisation regimen
were pooled and compared. Statistical analysis by Mann-Whitney
rank test revealed a significant difference between the number of
reactive sites, with sheep receiving rHA in FA exhibiting
significantly more reactive sites per animal, many at all injection
sites, than those sheep receiving antigen mixed with CV
(Figure 5A; P,0.05). Interestingly, there was a trend toward
lower reactivity scores of CV sites than of FA sites (Figure 5B),
although altogether, the variation of CV reactivity scores was
greater than (SD=1.750) than that of FA scores (SD=1.136).
Prophylactic and Therapeutic Administration of Anti-
haemagglutinin Hyperimmune Serum Protected Mice
from a Lethal Influenza Challenge
Even though hyperimmune serum consistently prevented
influenza-induced haemagglutination of RBC in vitro, we wished
to determine the in vivo potential of this serum to prevent lethal
influenza infection. To assess the protective ability of polyclonal
anti-HA antibodies, mice received pooled hyperimmune serum
from sheep immunised with rHA emulsified in CV or FA, or
pooled non-immune serum or PBS diluent as controls. Twenty-
four hours later, mice were challenged with 500 50% tissue-culture
infective doses (TCID50) of live PR8 by intranasal administration
and the clinical course was closely monitored (Figure 6A). Results
indicated that mice which received prophylactic hyperimmune
serum from either CV- or FA-immunised sheep exhibited some
weight loss immediately after influenza infection, although this loss
was quickly regained (Figure 6Ai and 6Aii respectively). In
contrast, those mice that received non-immune serum or PBS
had sustained weight loss and all had reached their pre-determined
clinical endpoints by day 10 (Figure 6Aiii and 6Aiv respectively).
Mantel-Cox survival analysis showed that both CV and FA
hyperimmune serum prevented the lethal consequences of
influenza infection in contrast to the effects of administration of
non-immune serum or PBS (Figure 6Av; P,0.001).
To determine whether these polyclonal antibodies could treat
an active influenza infection, hyperimmune or non-immune serum
or PBS was administered twenty-four hours after viral challenge
with 500 TCID50 PR8 (Figure 6B). Similarly, results indicated that
infected mice which received hyperimmune serum therapy
Figure 4. Low antigen dose produces similar anti-HA antibody
titres. Sheep (n=5) were immunised SC with 200 or 20 mg of rHA in
complete FA (A) or CV (B). Sheep were then boosted SC every two
weeks to a total of five boosts in incomplete FA or CV (indicated by
arrows). Pre-immune (time 0) or hyperimmune serum samples at a 1/
50,000 dilution were analysed for anti-HA IgG via ELISA (Ai, Bi) and HAI
(Aii, Bii). Data are represented as the mean 6 SEM endpoint dilution.
Data of both assays were analysed by two-way repeated-measures
ANOVA with Bonferroni post-tests; significance is denoted as thus:
*=P,0.05, **=P,0.01, ***=P,0.001, ns=not significant.
doi:10.1371/journal.pone.0068895.g004
Figure 5. Repeated subcutaneous immunisation with CoVac-
cine HT
TM elicits fewer reactive immunisation sites than
Freund’s adjuvant. Sheep (n=15) were immunised SC with rHA
antigen either in complete/incomplete FA or CV. Two weeks following
the final boost immunisation, injection sites were examined and
palpable lumps were enumerated (A) and graded (B). A scoring system
was devised based on the size and characteristics of the reaction sites
to rank the level of reactivity of each individual site. Grades of site
reactivity: 0– no reaction; 1– slight skin irregularity; 2– lump,10 mm
diameter or larger skin irregularity; 3– multiple small lumps/single
lump,40 mm; 4– lump,80 mm; 5–$80 mm lump. The data was
analysed by Mann-Whitney rank test; significance is denoted as thus:
*=P,0.05, **=P,0.01, ***=P,0.001, ns=not significant.
doi:10.1371/journal.pone.0068895.g005
Influenza Neutralising Antibodies from Sheep
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whereas most mice that received non-immune serum or PBS had
sustained weight loss and were euthanased by day 10 (Figure 6Biii,
6Biv). Similar to the effects of prophylactic administration of
hyperimmune serum, Mantel-Cox survival analysis revealed a
significant improvement in survival of the mice that received
hyperimmune serum compared to control mice (Figure 6Bv;
P,0.05). Taken together, it is clear that ovine hyperimmune
serum can protect against and treat lethal influenza infections in
mice.
Hyperimmune Anti-haemagglutinin Serum Elicited with
CoVaccine HT
TM Exhibits Greater Potency in vivo as
Compared to that Elicited by Freund’s Adjuvant
Anti-HA serum elicited with CV as an adjuvant had signifi-
cantly better potency in vitro (Figure 2); to determine if this
translated to increased potency in vivo, mice (n=6) were intrana-
sally inoculated with 500 TCID50 PR8 influenza and twenty-four
hours later treated with different doses of high titre pooled serum
(IP, equivalent to 1000, 500, 250 or 50 ml serum in a 1 ml
injection) elicited with either CV or FA. Groups of mice received
PBS or non-immune sheep serum as controls. Clinical disease
Figure 6. Prophylactic or therapeutic administration of ovine anti-HA serum is protective against lethal influenza challenge. Mice
(n=5) were prophylactically administered pooled serum (1 ml, IP) from either young sheep receiving 200 mg rHA SC in CV (Ai) or FA (Aii), day zero
pre-bleeds from corresponding sheep from both groups (Aiii) or PBS as a control (Aiv). Twenty-four hours later mice were challenged with a lethal
dose of PR8 (500 TCID50). Mice reaching a predetermined endpoint of 20% weight loss (dotted line) were euthanased as indicated by arrows. Mice
(n=5) were challenged with 500 TCID50 PR8 and twenty-four hours later therapeutically administered serum or PBS control as above (Bi–iv). In each
panel, data show percentage weight loss of individual mice. Survival curves of mice are also shown (Av, Bv). Mantel-Cox survival analysis was
performed on survival curves; significance between all curves is denoted as thus: *=P,0.05, **=P,0.01, ***=P,0.001, ns=not significant.
doi:10.1371/journal.pone.0068895.g006
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endpoints described above.
Most notably, mice that had therapeutically received CV serum
were completely protected from lethality from infection
(Figure 7Ai–Di), regardless of dose, whereas the lower doses of
250 mlt o5 0 ml of FA serum were not completely protective
(Figure 7Cii–Dii). Furthermore, although the 500 and 1000 mlF A
serum dose protected mice from lethality of infection (Figure 7Aii–
Bii) weight loss in these mice was more severe than that observed
in mice receiving equivalent doses of CV serum (Figure 7Ai–Bi).
Mantel-Cox survival analysis revealed a significant difference
between survival curves of all of the CV serum mice and controls
(data not shown). Comparison of the survival curves of FA and CV
serum mice revealed a significant survival advantage of CV serum
at a 50 ml dose (Figure 7Diii; P,0.001). A minimum dose of
500 ml of FA serum was required for complete protection whereas
a ten-fold lower dose of CV serum also offered complete
protection. These data are consistent with the HI results that
demonstrate an approximate ten-fold higher neutralising antibody
titre in serum from sheep immunised with antigen in CV as
compared to FA.
Taken together, these data suggest that lower doses of CV-
elicited sera provide protection against influenza and that
implementation of this adjuvant in ovine polyclonal antibody
production could dramatically increase the efficiency of eliciting
functional neutralising antibodies in sheep.
Discussion
Ovine polyclonal antibodies are frequently generated for
commercial and small laboratory scale applications, yet there
has been limited investigation into maximising the amount of
antibody generated through optimised ovine immunisation regi-
mens. Within this study, methods to improve ovine antibody
production were empirically investigated and demonstrated that
such ovine polyclonal antibodies effectively bound influenza virus
in vitro and prevented the death of mice infected with influenza
virus.
The route of immunisation has been shown to influence the
nature and intensity of the immune response generated to an
antigen [29,45,46]. In the current study, subcutaneous prime
immunisation with antigen in FA yielded significantly higher
overall anti-HA antibody titres when compared to intraperitoneal
prime. These findings are in contrast to an earlier study which
demonstrated that anti-C. parvum antibody titres at parturition [45]
were sixteen-fold higher in the serum when sheep received
intraperitoneal immunisation compared to intramuscular immu-
nisation. Furthermore, at twenty days post-lambing, detectable
anti-C. parvum IgG had stabilised to approximately two-fold higher
in the intraperitoneal-administered group. This discrepancy may
be a consequence of altered immunological function in the sheep
during pregnancy, or the differing nature of the antigens used [46].
It is possible that the rHA antigen is more efficiently presented by
cells of the subcutaneous tissues than those in the peritoneal
environment [28,29], as CD14-positive DCs present in the dermis
are directly involved in the differentiation of antibody-producing
plasma cells [50,51]. Furthermore, the hydrophobic properties of
FA may enable the stable deposition of the antigen-adjuvant
mixture at immunisation sites which is likely to be more favourable
for long term immunity [52]. That is, the sheep subcutaneously
primed may have had more local and stabilised antigen depots
than the intraperitoneally-primed sheep as comparatively the
peritoneal environment allows substances to disperse more freely.
The use of a novel experimental adjuvant CV was compared to
FA, the adjuvant routinely used for the commercial and
experimental production of polyclonal ovine antibodies. Interest-
ingly, CV was found to raise significantly higher specific serum
antibody titres than FA. The CV serum was also confirmed to
exhibit higher potency in vivo. The enhanced efficacy of CV to
induce high functional antibody titres may be partially attributable
to the integrity of the antigen once mixed with this particular
adjuvant. Protein antigens may be fully or partially denatured in
water-in-oil adjuvants such as FA, which may lead to the
deformation of native epitopes [53] resulting in antibodies with a
poor affinity for the native protein. In contrast, CV is an oil-in-
water emulsion of hydrophobic and negatively-charged sucrose
fatty acid sulphate esters formulated with submicron emulsions of
squalane that is combined with aqueous antigen and thus would
result in less protein denaturation than FA [41]. The accessibility
of the antigen to immune cells may also have contributed to
increased efficacy of CV compared to FA. While the tendency of
FA to form viscous deposits of antigen-adjuvant mixture in the
tissues results in sustained slow-release of antigen, it may also result
in limited antigen exposure to the cellular environment. In
contrast, antigen mixed with CV is in an aqueous environment
and this may facilitate dispersal into the tissues and increase the
amount of antigen immediately accessible to antigen processing
immune cells, thus increasing antibody titres. Indeed, recent
preclinical studies have also shown that this adjuvant can enhance
vaccine responses in not only sheep as described here but also in
pigs [41], mice [42,47], ferrets [36] and macaques [43]. The likely
enhanced dispersal of CV as compared to FA may also explain
why CV induced significantly fewer reactive sites that FA, which
importantly suggests a superior safety profile to FA. These
observations highlight CV as a safer and highly effective potential
alternative to FA for adjuvanting antigens, particularly when
factoring in the time-consuming and often hazardous emulsifica-
tion periods needed with FA and other water-in-oil adjuvants prior
to administration. Furthermore, these advantages combined with
the ability to elicit a high titre IgG antibody response in a broad
range of other animal species, favours the future practical
application of CV to the rapid and large scale production of
passive immunotherapeutics for veterinary and clinical use.
There were no significant age-related differences in the anti-HA
antibody titres achieved after immunisation with either CV- or
FA-rHA. Depending on size and growth characteristics, the
quantity of blood routinely obtained from younger sheep may be
upwards of a third less than that obtained from adult sheep [54].
However, the ability to utilise younger sheep for commercial
polyclonal antibody production means that significant increases in
antibody output over the lifespan of the animal would be possible,
thus offsetting agistment costs much sooner. This would be
particularly important if younger sheep were employed together
with adjuvants such as CV that increase overall antibody titre. The
costs associated with ovine antibody production could be
minimised further if high antibody titres could be maintained
with reduced amounts of costly antigen. Here, we showed that a
ten-fold lower dose of antigen than that used conventionally
resulted in only slightly lower (albeit significantly lower with CV
adjuvant) anti-HA antibody titres in sheep. However, the
magnitude of this difference is unlikely to matter particularly
when compared to the difference in the amount of antigen used
and instead reflects the complex relationship between antigen
dosage and antibody titre [33]. Furthermore, the optimal antigen
dosage will be affected by different adjuvants and antigens with
correspondingly different pathways used for antigen processing,
presentation and antibody responses [55]. Our results clearly
Influenza Neutralising Antibodies from Sheep
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e68895Influenza Neutralising Antibodies from Sheep
PLOS ONE | www.plosone.org 8 July 2013 | Volume 8 | Issue 7 | e68895indicate that the lower HA antigen dose induced anti-HA ovine
antibody titres similar to the high titres induced with the higher
antigen dose. Moreover, we expect that this reduced need for
antigen will have the added benefit of markedly reducing
production costs. Importantly, all immunisation regimens tested
here resulted in the production of potent anti-HA antibodies that
were able to treat and prevent lethal influenza infection in mice.
Antigenic variability among influenza strains remains one of the
major challenges facing the development of an influenza-specific
passive immunotherapeutic. However, it has been already been
shown that it is possible to elicit strain cross-reactive anti-influenza
hyperimmune serum by administering different subtypes of
influenza haemagglutinin [56,57]. In addition, administration of
an antigen (whether it be a whole pathogen or parts thereof) to a
live animal benefits from ‘natural selection’ by the host for the
most immunogenic targets and mimics the natural immune
response to infection or vaccination [58]. The widespread
application of passive immunotherapy to treat influenza may be
of particular benefit during pandemic outbreaks of the infection,
such as the recent 2009 H1N1 pandemic [59]. During an
influenza pandemic, a premium is attached to the timely and
large-scale production and distribution of an effective therapy.
Knowing best how to rapidly make at least cost large quantities of
potent ovine neutralising antibodies against influenza virus or
other potential pandemic pathogens could be an important
contribution to reducing the disease burden and its associated
societal and economic costs.
Supporting Information
Figure S1 Preliminary ELISA of anti-HA ovine serum
samples. An ELISA was performed on selected samples for assay
development. Serial dilutions of pre-immune or hyperimmune
sheep serum were added to duplicate wells of a rHA-coated
ELISA plate and specific antibody was detected with HRP-linked
anti-ovine IgG antibody. Signal was developed with OPD
substrate until colour was visible in serum-free wells. Absorbance
readings from blank wells were subtracted from all readings. The
results indicated that a 1/50,000 serum dilution gave OD readings
within the linear portion of the generated curve for hyperimmune
samples. Consequently a 1/50,000 dilution was used in subsequent
assays to assess experimental samples.
(TIF)
Table S1 Assessment of the effects of Receptor Destroy-
ing Enzyme on Haemagglutination-inhibition endpoint
titres. In order to determine the effects of receptor-destroying
enzyme (RDE) on endpoint HAI titres; selected serum samples
were assayed with or without treatment with RDE (Sigma, 37uC,
O/N). Samples were then treated with chicken red blood cells and
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